Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

Trial Details

NCT ID
NCT05277766
Phase
PHASE1
Sponsor
University Hospital, Ghent
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • PIPAC with Nal-IRI
Locations (sample)
  • Ghent, East-Flanders, Belgium|51.05,3.71667

Key Eligibility Criteria

  • Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable…
  • Estimated life expectancy \> 6 months; \> 3 months if primary cancer is pancreatic
  • Age ≥ 18 years
  • Adequate performance status (Karnofsky index \> 60% and WHO performance status \< 2)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →